Clinical data | |
---|---|
Routes of administration | Injection[1][2] |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | <3% (oral)[1] |
Elimination half-life | 44 minutes (IV)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C45H60N10O14 |
Molar mass | 965.031 g·mol−1 |
3D model (JSmol) | |
| |
|
Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclohexapeptide drug which acts as a highly selective NK2 receptor antagonist.[2][3][4] It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.[3][5][6]